PVLA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 67.29%, SMA50 58.7%, SMA200 135.85%). The stock’s 14-day RSI is 82.33 (overbought), while the ATR of 9.89 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 14.71% below its high and over 713.94% above its low. Average 10-day trading volume of 190.43 thousand shares is below the 3-month average of 246.66 thousand, indicating normal recent market interest.

Palvella Therapeutics, Inc. has 14.41 million shares outstanding. The public float is 10.62 million shares, elevated short interest at 16.24% of float. This equals 2.07 million shares. The short ratio is 8.54 days. Institutional investors hold 109.94% of the float. Insiders own 11.65%. JENKINS GEORGE M holds 187.62 thousand shares, HERON ELAINE J has 47.81 thousand shares and Goin Kathleen has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 2.69 thousand shares across 6 transactions.

Palvella Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 29.42%. Wall Street analysts project EPS growth of 13.97% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 30 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $270.00 to $73.00. The high target offers 71.71% upside. The low target suggests -53.57% downside. The mean target is $170.41. This offers 8.38% upside. Palvella Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 04, 2026, missed forecasts by 29.91%. The prior quarter beat by 33.33%. Over the last six quarters, Apple has recorded several small beats. These include -78.24% in May 15, 2025.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) closed at $157.24 USD, gaining $1.77 (1.14%) from the previous close of $155.47. The stock is currently within 5% of its 52-week high $52.36 and $161.38. With a market capitalization of about $2.26 billion, Palvella Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.17). Key stats such as the average daily volume over the past year has been around 248.78 thousand shares, volume is running light vs its 52-week average. Headquartered in Wayne, PA, Palvella Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Wesley H. Kaupinen, the company employs approximately 29 people and listed since January 02, 2015. Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions.

Palvella Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.10. This means the shares are trading above this model’s fair value.

Palvella Therapeutics, Inc. trades at a P/E ratio of -32.3, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.33 reflecting a rich premium to book value. The P/FCF stands at -61.27, also below market averages. Compared to sector medians, Palvella Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares are flat -6.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Palvella Therapeutics, Inc. trading at a premium to the broader market with a P/E of -32.3. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $131.05, suggesting -16.66% downside. Our AI forecast model points to short-term weakness (-1.14% over two weeks), a medium-term fall (-4.13% over three months), and a longer-term gain (52.56% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Palvella Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.14%, with price expected at $155.44 by September 17, 2026, within a range of $148.05 to $162.61 3-Month Outlook: Projected fall of -4.13%, reaching $150.74 by December 02, 2026, with a range of $148.63 to $152.95. 1-Year Outlook: Projected gain of 52.56%, with price at $239.88 by September 03, 2027, within a range of $235.46 to $245.06.